Hjertealbyl (Acetylsalicylic Acid)

Hjertealbyl is indicated for several therapeutic purposes that involve pain, fever, inflammation, and cardiovascular risk reduction.

• Relief of mild to moderate pain such as headache, toothache, or musculoskeletal discomfort.
• Reduction of fever associated with common infections or inflammatory conditions.
• Management of inflammatory disorders like arthritis when used short‑term.
• Primary or secondary prevention of thrombotic cardiovascular events, including myocardial infarction and ischemic stroke, in appropriate patients.
• Adjunctive therapy in certain post‑operative or percutaneous coronary interventions to maintain vessel patency.

• Acetylsalicylic acid exerts its antiplatelet effect by irreversibly acetylating the cyclooxygenase‑1 (COX‑1) enzyme in platelets, which blocks the conversion of arachidonic acid to thromboxane A₂, a potent promoter of platelet aggregation. The inhibition of COX‑1 also reduces prostaglandin synthesis, contributing to analgesic, antipyretic, and anti‑inflammatory actions. Because platelets cannot synthesize new COX‑1, the effect persists for the lifespan of the platelet.

Adverse reactions to Hjertealbyl are generally dose‑related and may involve the gastrointestinal tract, skin, or bleeding tendencies. Most patients experience mild, transient symptoms, while a smaller proportion may develop serious complications that require medical attention. The likelihood of an event is influenced by dosage, duration of therapy, and individual risk factors such as a history of ulcer disease or concurrent anticoagulant use.

Common

• Dyspepsia, abdominal discomfort, or heartburn.
• Nausea or mild vomiting.
• Minor bruising or prolonged bleeding from cuts.
• Skin rash or mild urticaria.
• Headache or dizziness.

Serious

• Gastrointestinal ulceration or bleeding.
• Intracranial hemorrhage.
• Severe allergic reactions such as anaphylaxis.
• Renal impairment or acute kidney injury.
• Hepatotoxicity presenting as elevated liver enzymes.

When prescribing or using Hjertealbyl, clinicians and patients should consider several precautionary measures to minimize risk and ensure safe therapy.

• Assess for a history of peptic ulcer disease, gastrointestinal bleeding, or gastritis before initiating therapy.
• Evaluate renal and hepatic function, especially in elderly patients or those with chronic disease.
• Use the lowest effective dose for the shortest duration required for the intended indication.
• Avoid use in individuals with known hypersensitivity to aspirin or other NSAIDs.
• Monitor for signs of bleeding, such as unusual bruising, hematuria, or melena.
• Counsel patients to take the medication with food or a proton‑pump inhibitor if gastrointestinal irritation occurs.

Hjertealbyl can affect the pharmacokinetics or pharmacodynamics of other medicines; certain combinations should be avoided, while others require careful monitoring.

Avoid

• Concurrent use with other antiplatelet agents (e.g., clopidogrel) or anticoagulants (e.g., warfarin, direct oral anticoagulants) due to increased bleeding risk.
• Combination with non‑steroidal anti‑inflammatory